Pathology News
editor

About Editor

This author has not yet filled in any details.
So far Editor has created 851 blog entries.

August 2025

Emerging Biotechs, Small & Mid-Size CROs: We Now Have a Concentriq LS Package for You

2025-08-27T16:00:55+00:00

By Ritida Nanda Emerging biotechs, along with their small and mid-sized CRO counterparts, are establishing themselves as key players advancing the next generation of therapies. So, in line with our mission to rewire pathology for precision medicine, we’re fully empowering them with our Concentriq LS platform. Trusted by 16 of the top 20 pharmaceutical companies, [...]

Emerging Biotechs, Small & Mid-Size CROs: We Now Have a Concentriq LS Package for You2025-08-27T16:00:55+00:00

Announcing Orchard Enterprise Go-Live for P&C Labs

2025-11-26T11:17:14+00:00

Pathology and Cytology Laboratories Successfully Goes Live with Clinisys™ Orchard Enterprise Solutions and Proscia Integration. Clinisys™-Orchard Software is pleased to announce that Pathology and Cytology Laboratories (P&C Labs) completed a successful go-live of Orchard® Enterprise Lab, Orchard® Enterprise Pathology, and Orchard® Outreach, including integration to Proscia Digital Imaging system. This milestone marks a significant advancement in P&C Labs’ commitment to [...]

Announcing Orchard Enterprise Go-Live for P&C Labs2025-11-26T11:17:14+00:00

Study Confirms Reliability of Digital TIL Scoring in Post-Treatment Breast Cancer Assessment

2025-08-18T08:58:56+00:00

by Christos Evangelou, MSc, PhD – Medical Writer and Editor In a recent study, researchers at the Institut Jules Bordet in Belgium validated the reliability of digital scoring of tumor-infiltrating lymphocytes (TILs) in breast cancer tissue after chemotherapy treatment. The study showed that trained pathologists can consistently evaluate immune cell presence in residual tumor tissue, [...]

Study Confirms Reliability of Digital TIL Scoring in Post-Treatment Breast Cancer Assessment2025-08-18T08:58:56+00:00

Modella AI and Techcyte Announce a Research Collaboration with Modella AI’s State-of-the-Art Agentic and Generative AI-Powered Diagnostic Pathology Platform

2025-09-17T09:36:07+00:00

Techcyte, a leading provider of AI-powered digital diagnostics for anatomic and clinical pathology, today announced that its platform, Techcyte Fusion™ (research use only (RUO) in the US, CE-IVDD-marked in Europe), now includes Modella AI, a biomedical artificial intelligence company at the forefront of computational pathology, as a partner in the Techcyte Fusion Partner Program. This collaboration brings [...]

Modella AI and Techcyte Announce a Research Collaboration with Modella AI’s State-of-the-Art Agentic and Generative AI-Powered Diagnostic Pathology Platform2025-09-17T09:36:07+00:00

From Potential to Pipeline: How Pathology AI Is Rewiring Drug Discovery and Development

2025-08-27T12:28:12+00:00

Everyone’s talking about AI in therapeutic R&D, but it’s not always easy to cut through the hype to understand where it’s making a real impact today. One of the clearest signals of progress? Pathology. In a recent Drug Discovery World webinar, our Chief Strategy Officer Nathan Buchbinder sat down with industry leaders Vipul Baxi (Amgen), Dr. Deirdre De Steno (Owkin), and Dr. Ken Bloom (Nucleai) to [...]

From Potential to Pipeline: How Pathology AI Is Rewiring Drug Discovery and Development2025-08-27T12:28:12+00:00

Techcyte and Modella AI Announce a Research Collaboration with Modella AI’s State-of-the-Art Agentic and Generative AI-Powered Diagnostic Pathology Platform

2025-09-17T09:38:37+00:00

Techcyte, a leading provider of AI-powered digital diagnostics for anatomic and clinical pathology, today announced that its platform, Techcyte Fusion™ (research use only (RUO) in the US, CE-IVDD-marked in Europe), now includes Modella AI, a biomedical artificial intelligence company at the forefront of computational pathology, as a partner in the Techcyte Fusion Partner Program. This collaboration brings [...]

Techcyte and Modella AI Announce a Research Collaboration with Modella AI’s State-of-the-Art Agentic and Generative AI-Powered Diagnostic Pathology Platform2025-09-17T09:38:37+00:00

Deep Learning Assessment of Metastatic Relapse Risk From Digitized Breast Cancer Histological Slides

2025-08-27T12:28:21+00:00

Valentin Gaury (Senior Data Scientist) and colleagues at Owkin, in collaboration with Dr. Ingrid Garberis and researchers from Gustave Roussy, Paris-Saclay University (Villejuif, France), have recently published a paper on the deep learning assessment of metastatic relapse risk using digitized breast cancer histological slides. Following this recent publication, Pathology News will host a webinar where Valentin Gaury will [...]

Deep Learning Assessment of Metastatic Relapse Risk From Digitized Breast Cancer Histological Slides2025-08-27T12:28:21+00:00

EVIDENT Announces Acquisition of Pramana, Inc.

2025-08-18T13:27:12+00:00

Evident announces a definitive agreement to acquire Pramana, Inc., a leading manufacturer of digital pathology solutions. Pramana’s cutting-edge autonomous whole slide imaging technologies, combined with Evident’s longstanding leadership in clinical microscopy and superior optics, will revolutionize the market for digital pathology solutions and usher in a new era—digital pathology 2.0. Founded in 2021 by nference (a [...]

EVIDENT Announces Acquisition of Pramana, Inc.2025-08-18T13:27:12+00:00

What Happens When a Pathologist Talks to a Tablet?

2025-08-27T12:28:29+00:00

A structured report is created – in seconds. No joke. No buzzword. Reality in Bremen, Germany. At Klinikum Bremen-Mitte and the MVZ Fachärztezentrum Hanse, elea, our AI-powered software for pathology, is up and running. It doesn’t just listen. It understands. Samy Hakroush, Chief Physician of Pathology, dictates – and elea instantly understands what it’s about: [...]

What Happens When a Pathologist Talks to a Tablet?2025-08-27T12:28:29+00:00

OriGene and HistoWiz Announce New Integration to Streamline Antibody Access Through PathologyMap™

2025-08-22T09:22:27+00:00

HistoWiz is excited to announce a new collaboration with OriGene, a leading supplier of research antibodies and molecular biology tools. Through this partnership, a curated list of OriGene’s antibodies is now integrated into HistoWiz’s PathologyMap™ platform, giving researchers streamlined access to validated reagents directly within their digital pathology workflow.PathologyMap™, HistoWiz’s digital pathology image management platform, enables scientists [...]

OriGene and HistoWiz Announce New Integration to Streamline Antibody Access Through PathologyMap™2025-08-22T09:22:27+00:00
Go to Top